Evercore ISI analyst Josh Schimmer met with Heron Therapeutics management and sees substantial opportunity for HTX-011 to transform the surgical landscape. The analyst said ‘011 is poised to enter the market in 1H 2019 and has blockbuster potential and said survey work suggests a strong adoption opportunity. Schimmer believes Heron is one of the most compelling names in the space and remains a top midcap pick with an Outperform rating and $80 price target.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.